Keyword: Daniel O'Day
What can Gilead investors expect to see from incoming CEO Daniel O’Day? Patience, but also more deal hunting, according to the big biotech’s execs.
Call it a swap. Alexander Hardy is taking the top spot at Genentech in an executive shuffle triggered by the departure of Dan O'Day.
Roche's first-half sales climbed 7% to $28.3 billion, their fastest clip in about three years, thanks to stepped-up performance from its newer drugs.
Roche says it's in the midst of one of the most successful multiple sclerosis launches ever—and MS has had some doozies.